A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
Yuan Sheng(Changhai Hospital), Yueyin Pan(University of Science and Technology of China), Xinhong Wu(Jiangnan University), Haibo Wang(Fujian Medical University), Jingfen Wang, Anqin Zhang(Guangdong Province Women and Children Hospital), Huihua Xiong(Tongji Hospital), Yudong Wu(Anhui Medical University), Jiuwei Cui(Jilin University), Xiaohong Wu(Jiangnan University), Peifen Fu(First Affiliated Hospital Zhejiang University), Jin Yang(Shanxi Medical University), Jing Cheng(Wuhan Puai Hospital), Tao Sun(Wuhan University), Xinlan Liu(Yunnan Agricultural University), Yuee Teng(First Hospital of China Medical University), Yongmei Yin(Nanjing Medical University), Aimin Zang, Min Yan(Shanxi Agricultural University), Lilin Chen(First Affiliated Hospital of Xiamen University), Xueli Mo(Peking University Shougang Hospital), Yongsheng Wang(Shandong Tumor Hospital), Qingshan Li(Shanxi University), Chuan Wang, Cuizhi Geng(Hebei Medical University), Lili Zhang(Guangxi Medical University), Kun Wang(Union Hospital), Hui Li(Sichuan Cancer Hospital), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Kangsheng Gu(Anhui Medical University), Ying Lin(Fujian University of Traditional Chinese Medicine), Yiding Chen(Second Affiliated Hospital of Zhejiang University), Fanfan Li(Anhui University), Jianyun Nie(Kunming Medical University), Ying Cheng(Jilin Province Tumor Hospital), Xin Zhou(Chongqing University), Gang Sun(Xinjiang Medical University), Yongqiang Zhang, Danmei Pang(First People's Hospital of Foshan), Xiaojia Wang(Zhejiang Chinese Medical University), Man Li(Dalian Medical University), Tienan Yi(Xiangyang Central Hospital), Helong Zhang(Chinese People's Liberation Army), Chunwei Xie, Junlan Yang(People's Liberation Army No. 150 Hospital), Quchang Ouyang(Hunan Cancer Hospital), Qiang Liu(Dalian Medical University), Jun Qian(First Affiliated Hospital of Bengbu Medical College), Shusen Wang(Sun Yat-sen University)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743